Trial Profile
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Dec 2014
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Fluorouracil; Folinic acid
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mebiopharm
- 01 Dec 2014 Planned End Date changed from 1 Mar 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 26 Apr 2012 Additional location (Georgia) added as reported by ClinicalTrials.gov.
- 24 Apr 2012 Planned end date changed from 1 Mar 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.